Last updated: August 6, 2026
OPVEE, Indivior’s nalmefene hydrochloride nasal spray, is an FDA-approved emergency treatment for opioid overdose in adults and adolescents aged 12 years and older. Its commercial thesis rests on nalmefene’s longer pharmacologic activity than naloxone, particularly in fentanyl-related overdoses. Its principal market risks are entrenched naloxone use, OTC availability of Narcan, public-sector purchasing constraints, and uncertain evidence that longer duration produces superior real-world outcomes.
OPVEE remains a small product within Indivior’s portfolio. The drug has strategic value as a differentiated overdose-response product, but its revenue contribution is substantially below Sublocade and other opioid-use-disorder products.
What is OPVEE and how does it work?
OPVEE is a single-dose, intranasal formulation of nalmefene hydrochloride. Each device delivers 2.7 mg of nalmefene hydrochloride into one nostril. A second dose may be administered after two to five minutes if the patient does not respond or relapses into respiratory depression.
Nalmefene is an opioid receptor antagonist. It has high affinity for the mu-opioid receptor and a longer duration of action than naloxone. OPVEE is intended for emergency use while awaiting emergency medical assistance, not as a substitute for definitive medical care. The prescribing information warns that nalmefene can precipitate severe opioid withdrawal in opioid-dependent individuals (U.S. Food and Drug Administration [FDA], 2023).
How does OPVEE compare with naloxone?
| Attribute |
OPVEE |
Narcan and generic naloxone nasal sprays |
| Active ingredient |
Nalmefene |
Naloxone |
| Route |
Intranasal |
Intranasal |
| Standard single dose |
2.7 mg |
Commonly 4 mg |
| FDA overdose indication |
Adults and adolescents aged 12 and older |
Adults and pediatric patients, depending on product |
| Duration of opioid antagonism |
Longer than naloxone |
Generally shorter |
| OTC status |
Prescription product |
Narcan approved OTC in 2023 |
| Core commercial argument |
Longer activity and potential coverage for prolonged opioid toxicity |
Familiarity, established protocols, distribution, lower price |
| Primary commercial barrier |
Limited real-world adoption and price sensitivity |
Less differentiated product category with intense competition |
Nalmefene’s longer half-life creates a potential advantage when overdose involves fentanyl or other potent synthetic opioids. It also creates a safety and medical-management tradeoff because prolonged antagonism can produce more persistent withdrawal symptoms. Public-health purchasers may prioritize rapid access, low cost, and operational familiarity over longer receptor blockade.
When did FDA approve OPVEE?
The FDA approved OPVEE on May 22, 2023, under NDA 214697. Indivior launched the product in the United States in 2023. The approved indication covers emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, in adults and pediatric patients aged 12 years and older (FDA, 2023).
What is the FDA regulatory status of OPVEE?
| Regulatory item |
Status |
| Product |
OPVEE nasal spray |
| Active ingredient |
Nalmefene hydrochloride |
| NDA |
214697 |
| Approval date |
May 22, 2023 |
| FDA pathway |
505(b)(2) new drug application |
| Applicant |
Indivior Inc. |
| Indication |
Emergency treatment of known or suspected opioid overdose |
| Minimum labeled age |
12 years |
| Prescription or OTC |
Prescription |
| Pediatric exclusivity |
No separate six-month pediatric exclusivity identified in the approval materials |
| Controlled-substance status |
Nalmefene is not an opioid agonist and is not scheduled as a controlled substance |
The 505(b)(2) pathway allowed reliance on existing knowledge regarding nalmefene while requiring product-specific data for the nasal delivery system, dosing, manufacturing, and labeling.
What patents protect OPVEE?
OPVEE’s protection is based on product formulation, nasal delivery, and related pharmaceutical composition claims rather than on a newly discovered opioid-receptor mechanism. The product originated with Opiant Pharmaceuticals, which Indivior acquired in 2023.
A key Orange Book-listed patent is U.S. Patent No. 11,925,656, which covers nalmefene nasal formulations and related delivery technology. The patent has a term extending into 2039 based on its underlying priority and issue-date calculations. Exact Orange Book listing data should be checked against the current FDA Orange Book because listing status, pediatric extensions, and patent-term adjustments can change over time (FDA, 2024a).
OPVEE patent and exclusivity profile
| Protection category |
Assessment |
| Active ingredient |
Nalmefene is an established active pharmaceutical ingredient; composition-of-matter protection is not the main barrier |
| Nasal formulation |
Core commercial protection |
| Device and delivery system |
Potentially relevant, depending on claim scope and Orange Book listings |
| Regulatory exclusivity |
No unusually long new-chemical-entity exclusivity period |
| Orange Book patent protection |
At least one listed patent covering the product technology |
| Expected patent tail |
Into approximately 2039 for the principal listed formulation patent |
| Biosimilar exposure |
None; OPVEE is a small-molecule drug |
| Generic exposure |
Possible after applicable patent and regulatory barriers expire |
The patent estate is strategically useful but narrower than a classic new molecular entity estate. Generic applicants could challenge formulation, dosage-form, or device claims through Paragraph IV certifications. The commercial strength of those claims will depend on prosecution history, claim construction, enablement, obviousness, and whether a competing product uses materially different nasal technology.
What formulations are protected by OPVEE patents?
The relevant protection centers on intranasal nalmefene formulations capable of delivering a therapeutically effective dose through a portable spray device. The commercial value of these claims is higher than the value of broad nalmefene claims because a generic competitor must reproduce the emergency nasal delivery profile while satisfying pharmaceutical equivalence and device requirements.
Potential design-around paths include:
- A different nalmefene concentration or excipient system.
- A separate nasal spray architecture.
- A different unit-dose container or actuator.
- An injectable or alternative non-nasal dosage form.
- A product with a different labeled age range or dosing regimen.
These alternatives may avoid particular formulation claims but would not necessarily eliminate FDA development, comparative pharmacology, device, and manufacturing hurdles.
When does OPVEE lose exclusivity?
OPVEE’s principal listed patent protection is expected to extend into 2039, subject to the current Orange Book record, patent-term adjustment, terminal disclaimers, and any changes in listing status. FDA regulatory exclusivity is shorter than the patent term and is not expected to block generic development for the entire period.
A practical generic-entry timeline is therefore:
| Period |
Market implication |
| 2023-2028 |
Early commercial buildout; patent and formulation barriers remain central |
| 2028-2033 |
Potential period for Paragraph IV activity, depending on generic development and patent interpretation |
| 2034-2038 |
Higher probability of intensified generic preparation if claims survive or are narrowed |
| Approximately 2039 |
Principal listed-patent expiry window, subject to Orange Book and patent-term details |
| Post-expiry |
Generic or alternative nalmefene nasal products become more feasible |
The first generic launch could occur before the nominal patent expiry if a challenger prevails in litigation, obtains a favorable settlement, or designs around the listed claims. A Paragraph IV filing would not itself establish market entry. It would trigger possible litigation and could delay approval under the Hatch-Waxman framework.
Which companies are challenging OPVEE?
No major publicly disclosed Paragraph IV litigation against OPVEE was identified in the FDA and publicly available court records reviewed for this analysis through 2024. Generic competition is more likely to emerge first against naloxone products because naloxone has a larger installed market, broader prescribing history, and established generic manufacturing base.
The principal competitive pressure on OPVEE comes from products rather than named patent challengers:
- Emergent BioSolutions’ Narcan, including OTC Narcan.
- Generic naloxone nasal sprays.
- Kloxxado, an 8 mg naloxone nasal spray marketed by Hikma Pharmaceuticals.
- ZIMHI, an injectable naloxone product from Adamis Pharmaceuticals, now associated with broader market access constraints.
- Community and public-sector naloxone programs using injectable or intranasal generic products.
What is the Orange Book status of OPVEE?
OPVEE is listed in the FDA Orange Book as a prescription drug approved under NDA 214697. The Orange Book listing identifies patents that the NDA holder asserts cover the approved product or use. The most commercially relevant listing is the formulation patent associated with nalmefene nasal delivery.
Orange Book status matters because an ANDA applicant must address listed patents through a Paragraph I, II, III, or IV certification. A Paragraph IV certification asserts that the listed patent is invalid, unenforceable, or not infringed. Indivior could bring a patent-infringement action within 45 days of receiving notice, potentially triggering a statutory stay of FDA approval for up to 30 months.
OPVEE has no biosimilar pathway because it is a small-molecule drug. Any competitor would generally use an ANDA or, depending on the product’s differences, a 505(b)(2) application.
How strong is the OPVEE patent estate?
The OPVEE estate is moderately strong for the commercial dosage form and weaker for the underlying molecule. Its strengths are:
- A long-dated formulation patent.
- Product-specific nasal delivery know-how.
- Device and manufacturing complexity that may increase development costs.
- The possibility of regulatory and litigation delays for an ANDA challenger.
Its weaknesses are:
- Nalmefene is not a newly discovered molecule.
- The product has a relatively simple single-dose presentation.
- Alternative nasal formulations may be technically feasible.
- The market may support a 505(b)(2) competitor with a differentiated formulation.
- Commercial value depends on reimbursement and public procurement, not only patent life.
The estate should be treated as a formulation-and-device barrier rather than a fully integrated molecule, formulation, method-of-use, and manufacturing fortress.
What market forces determine OPVEE sales?
OPVEE operates in a public-health market shaped by opioid mortality, fentanyl prevalence, state purchasing programs, emergency medical services, pharmacies, Medicaid, and harm-reduction organizations.
Fentanyl creates demand but not automatic switching
The increase in fentanyl-related overdoses supports the clinical rationale for longer-acting antagonism. It does not guarantee conversion from naloxone. Buyers may require direct evidence that OPVEE reduces repeat dosing, emergency interventions, or mortality in field conditions.
OTC Narcan changes the competitive baseline
The FDA approved Narcan 4 mg nasal spray for OTC sale in March 2023. OTC access expands consumer availability and increases brand recognition for naloxone. It also makes naloxone easier for employers, families, pharmacies, and community organizations to purchase without a prescription (FDA, 2023b).
OPVEE therefore competes against a product that has:
- Established clinical familiarity.
- Broad public-health distribution.
- OTC availability.
- A substantial generic market.
- Existing standing-order infrastructure.
Public-sector procurement is price sensitive
State and federal programs often purchase overdose-reversal products through tenders, negotiated contracts, grants, or centralized procurement. A premium-priced product must demonstrate operational or clinical advantages. Without a favorable formulary position, OPVEE may remain concentrated in selected emergency departments, correctional facilities, first-responder programs, and high-risk opioid-use populations.
Withdrawal risk affects clinical adoption
Longer receptor blockade can be valuable when opioid toxicity persists. It can also produce longer withdrawal in opioid-dependent patients. That risk may limit adoption among clinicians who prefer naloxone’s shorter duration and established titration practices.
What licensing deal brought OPVEE to Indivior?
Indivior acquired Opiant Pharmaceuticals in February 2023 for approximately $145 million in cash at closing, plus contingent value rights with potential additional payments of up to approximately $145 million. The transaction gave Indivior control of OPVEE and Opiant’s broader opioid-antagonist portfolio (Indivior, 2023).
The deal preceded FDA approval by several months. Indivior’s strategic rationale was to expand beyond opioid-use-disorder treatment into overdose rescue and to use its commercial infrastructure in addiction medicine, emergency care, and public-health channels.
What has OPVEE contributed to Indivior revenue?
OPVEE generated initial commercial revenue after its 2023 launch, but it remains small relative to Indivior’s overall business and Sublocade franchise. Indivior reported approximately $7 million in OPVEE net revenue in 2023. The product’s 2024 revenue increased from the launch-year base, but the company continued to classify OPVEE as an emerging product rather than a primary growth engine in the scale of Sublocade (Indivior, 2024).
Financial trajectory
| Financial period |
OPVEE status |
Interpretation |
| 2023 |
Initial launch revenue, approximately $7 million reported |
Market access and formulary placement phase |
| 2024 |
Growth from a low base |
Expansion into public-sector and first-responder channels |
| 2025 onward |
Dependent on procurement wins and evidence of differentiation |
Potential for growth, but highly sensitive to pricing and naloxone competition |
| Long term |
Patent-supported branded sales possible through the late 2030s |
Generic, 505(b)(2), and alternative nalmefene risk increases before expiry |
OPVEE’s financial impact is more strategic than transformational. Its revenue does not materially change Indivior’s dependence on Sublocade and opioid-use-disorder treatments. The product could become a meaningful specialty franchise if Indivior secures government purchasing contracts and demonstrates advantages in fentanyl-related overdose response. Without those developments, the likely outcome is a niche branded product with modest revenue relative to the broader overdose-reversal market.
What generic launch risks exist for OPVEE?
The most credible generic-entry scenarios are:
Early Paragraph IV challenge
A generic applicant could argue that the listed formulation patent is invalid or not infringed. This would create litigation risk before 2039. The probability of an early launch would depend on the patent’s claim breadth and whether Indivior secures a preliminary injunction or settlement.
505(b)(2) competitive product
A competitor could develop a different nalmefene nasal formulation or delivery device and seek approval through the 505(b)(2) pathway. This route could avoid direct reliance on the same product-specific technology while competing for the same clinical use.
Post-expiry ANDA entry
After the principal listed patent expires, an ANDA applicant could enter with a therapeutically equivalent nasal nalmefene product. Device equivalence and manufacturing controls would remain relevant, but the legal barrier would be lower.
Naloxone substitution
Naloxone does not need to infringe OPVEE patents to erode sales. OTC Narcan, generic naloxone, and public-sector contracts can displace OPVEE through formulary preference and lower acquisition cost.
What litigation and settlement risks affect OPVEE?
No publicly disclosed settlement agreement involving an OPVEE Paragraph IV challenger was identified through 2024. The principal future litigation issues are likely to involve:
- Validity of nasal formulation claims.
- Obviousness based on prior nalmefene and nasal delivery disclosures.
- Infringement by alternative spray devices.
- Patent-term calculations.
- Orange Book listing disputes.
- 30-month stay timing after a Paragraph IV notice.
A settlement could permit an agreed generic launch date before patent expiry. That date would depend on the relative strength of the patents, the economics of litigation, and the challenger’s ability to design around the claims.
How does OPVEE compare with Narcan and other overdose drugs?
| Product |
Company |
Active ingredient |
Market position |
Main advantage |
Main risk |
| OPVEE |
Indivior |
Nalmefene |
Branded prescription entrant |
Longer duration |
Price and limited switching evidence |
| Narcan |
Emergent |
Naloxone |
Leading branded nasal product, OTC |
Recognition and access |
Shorter duration and intense competition |
| Generic naloxone nasal spray |
Multiple manufacturers |
Naloxone |
Low-cost alternative |
Price and procurement access |
Less brand differentiation |
| Kloxxado |
Hikma |
Naloxone |
High-dose nasal competitor |
8 mg dose |
Same naloxone class and pricing pressure |
| Injectable naloxone |
Multiple manufacturers |
Naloxone |
EMS, hospitals, public programs |
Low acquisition cost and familiarity |
Administration burden |
OPVEE has the clearest pharmacologic differentiation, but Narcan has the stronger commercial position. The central market question is whether buyers value longer activity enough to offset the cost and withdrawal concerns.
Key Takeaways
- OPVEE is a prescription nalmefene nasal spray approved by the FDA in May 2023.
- Its primary differentiation is longer opioid-antagonist activity than naloxone.
- Narcan’s OTC approval and the availability of generic naloxone create major adoption and pricing pressure.
- OPVEE’s core patent protection is formulation and nasal-delivery based, with principal protection extending into approximately 2039 subject to the current Orange Book and patent-term record.
- No major publicly disclosed Paragraph IV litigation or settlement was identified through 2024.
- OPVEE generated approximately $7 million in 2023 revenue and grew from that launch base in 2024.
- The product is strategically relevant to Indivior but remains financially small compared with Sublocade.
- The most credible competitive threats are public-sector naloxone procurement, OTC Narcan, generic nasal naloxone, and a potential 505(b)(2) nalmefene competitor.
- Commercial upside depends on government contracts, first-responder adoption, reimbursement, and evidence supporting a clinical advantage in fentanyl-related overdoses.
FAQs
Is OPVEE stronger than Narcan for fentanyl overdoses?
OPVEE has longer opioid-antagonist activity, which may be useful in prolonged or recurrent opioid toxicity. That pharmacologic distinction does not establish universal superiority over Narcan in field use.
Can OPVEE be purchased over the counter?
No. OPVEE remains a prescription product. Narcan 4 mg nasal spray is available over the counter in the United States.
Does OPVEE have biosimilar competition?
No. OPVEE is a small-molecule drug, so competitors would use generic or 505(b)(2) regulatory pathways rather than the biosimilar pathway.
What is the biggest commercial risk to OPVEE?
The largest risk is substitution by lower-cost naloxone, especially OTC Narcan and generic products purchased through public-health and government channels.
Could a generic OPVEE launch before 2039?
Yes. A generic or 505(b)(2) competitor could launch earlier through a successful Paragraph IV challenge, a design-around strategy, or a settlement that permits entry before the principal listed patent expires.
References
-
Emergent BioSolutions Inc. (2023). Narcan naloxone hydrochloride nasal spray: FDA approval for nonprescription use. U.S. Food and Drug Administration.
-
Indivior PLC. (2023). Indivior completes acquisition of Opiant Pharmaceuticals. Indivior PLC.
-
Indivior PLC. (2024). Annual report and accounts 2023. Indivior PLC.
-
U.S. Food and Drug Administration. (2023a). OPVEE: Prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2023b). FDA approves first over-the-counter naloxone nasal spray. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Patent and Trademark Office. (2024). U.S. Patent No. 11,925,656. U.S. Department of Commerce.
